• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 23, 2018

View Archived Issues

Muscle CAR? Celgene’s $9B offer for Juno starts pundits weighing traction, final laps

Now that Celgene Corp. has made its $9 billion move to take over Juno Therapeutics Inc., advancing in the ever-hot chimeric antigen receptor (CAR) T-cell space, speculation has turned to the ultimate odds of dominance, eventual sales numbers if the CD19-targeting JCAR-017 wins FDA clearance, and how that new deal fits alongside Celgene’s existing anti-B cell maturation antigen (BCMA) pact with Bluebird Bio Inc. Read More

In the clinic

Nanobiotix SA, of Paris, reported intermediate data from a phase I/II trial testing NBTXR-3, hafnium oxide nanoparticles, in liver cancers, including primary hepatocellular cancer and liver metastasis from other tumors, at the ASCO Gastrointestinal Cancers Symposium in San Francisco. Of the seven evaluable patients, three achieved a complete response and three were partial responders. Read More

Sanofi snags hemophilia player Bioverativ with $11.6B bid

Piper Jaffray analyst Christopher Raymond called Sanofi SA’s takeover of Bioverativ Inc. for $11.6 billion “just what the doctor ordered” and a positive signal for the sector overall. Paris-based Sanofi disclosed early Monday that it will acquire Bioverativ by way of a tender offer expected next month for the Waltham, Mass.-based company’s outstanding shares (NASDAQ:BIVV) at $105 each – a 64 percent premium to Friday’s closing price of $62.75. Read More

Vical, Astellas see CMV vaccine fail in phase III HST study

Shares of San Diego-based Vical Inc. (NASDAQ:VICL) fell 23 percent, or 43 cents, to $1.44 Monday as longtime partner Astellas Pharma Inc. took the wraps off top-line data showing that ASP-0113, a vaccine designed to prevent cytomegalovirus (CMV) disease and associated complications in hematopoietic stem cell transplant (HCT) recipients, failed to meet primary or secondary endpoints of the phase III study. Read More

U.S. Senate shutdown compromise could delay full funding for FDA, NIH

After three days of a partial shutdown, it looks like it’s back to business as usual for the U.S. government – sort of. Read More

South Korean government to ease restrictions for gene therapies, organ donations

HONG KONG – South Korean authorities are expected to ease restrictions for the country’s biotech industry, especially for regulations surrounding gene therapies and organ donation. Read More

Financings

Eureka Therapeutics Inc., of Emeryville, Calif., disclosed the successful completion of a $60 million series D financing round. Read More

Other news to note

Klogene Therapeutics Inc., of Boston, and Boston University School of Medicine said a paper published in the Journal of Molecular Neuroscience showed efficient transcriptional activation of the anti-aging multifunctional gene Klotho by CRISPR/Cas9. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe